US2019376033A1PendingUtilityA1

PREPARATION OF FETAL NUCLEATED RED BLOOD CELLS (NRBCs) FOR DIAGNOSTIC TESTING

Assignee: KELLBENX INCORPORATEDPriority: May 15, 2014Filed: Dec 31, 2018Published: Dec 12, 2019
Est. expiryMay 15, 2034(~7.8 yrs left)· nominal 20-yr term from priority
C12Q 1/6883C12Q 2565/501G01N 2800/385C12Q 2531/113G01N 33/6893C12Q 2600/158C12Q 2600/156G01N 33/80G01N 2800/387C12Q 1/6806C12N 5/0641G01N 33/6878C07K 16/2896G01N 33/56966G01N 33/54326G01N 33/582C07K 16/2881
52
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The disclosure relates to methods of preparation of fetal nucleated red blood cells (NRBCs) from biological samples for diagnostic testing.

Claims

exact text as granted — not AI-modified
1 . A method of enriching for fetal nucleated red blood cells (fNRBCs) from a biological sample, comprising:
 (a) subjecting the biological sample to density separation to obtain a fNRBC-containing cell fraction;   (b) subjecting the fNRBC-containing cell fraction obtained in step (a) to magnetic activated cell sorting (MACS) using at least one fNRBC positive selection reagent to obtain a MACS-sorted cell population;   (c) fluorescently labeling cells in the MACS-sorted cell population obtained in step (b) with at least one fNRBC positive selection reagent to obtain a fluorescently labeled cell population; and   (d) sorting the fluorescently labeled cell population obtained in step (c) by flow cytometry to select for fNRBCs, thereby obtaining a population of cells enriched for fNRBCs.   
     
     
         2 - 3 . (canceled) 
     
     
         4 . The method of  claim 1 , wherein at least one fNRBC positive selection reagent of step (b) comprises monoclonal antibody 4B9, an anti-CD235a antibody, or a nuclear stain. 
     
     
         5 - 9 . (canceled) 
     
     
         10 . The method of  claim 1 , which does not comprise a negative selection step. 
     
     
         11 . The method of  claim 1 , wherein the fNRBC-containing cell fraction obtained in step (a) is subject to negative selection prior to step (b). 
     
     
         12 . The method of  claim 1 , wherein the MACS-sorted cell population obtained in step (b) is subject to negative selection prior to step (c). 
     
     
         13 . The method of  claim 11 , wherein the negative selection is negative immunoselection. 
     
     
         14 . (canceled) 
     
     
         15 . A method of enriching for fNRBCs from a biological sample, comprising:
 (a) subjecting the biological sample to density separation to obtain a fNRBC-containing cell fraction;   (b) subjecting the fNRBC-containing cell fraction obtained in step (a) to MACS using at least two fNRBC positive selection reagents to obtain a MACS-sorted cell population;   (c) performing micromanipulation on the MACS-sorted cell population obtained in step (b) to isolate individual fNRBCs or groups of fNRBCs.   
     
     
         16 . The method of  claim 15 , wherein at least one fNRBC positive selection reagent of step (b) comprises monoclonal antibody 4B9 or an anti-CD235a antibody. 
     
     
         17 . (canceled) 
     
     
         18 . The method of  claim 15 , which does not comprise a negative selection step. 
     
     
         19 . The method of  claim 15 , wherein the fNRBC-containing cell fraction obtained in step (a) is subject to negative selection prior to step (b). 
     
     
         20 . The method of  claim 15 , wherein the MACS-sorted cell population obtained in step (b) is subject to negative selection prior to step (c). 
     
     
         21 . The method of  claim 19 , wherein the negative selection is negative immunoselection. 
     
     
         22 . (canceled) 
     
     
         23 . The method of  claim 1 , wherein the biological sample is maternal blood. 
     
     
         24 - 25 . (canceled) 
     
     
         26 . The method of  claim 1 , which further comprises validating the identity of at least one fNRBC as a fetal cell. 
     
     
         27 . A cell population enriched in fNRBCs obtained or obtainable by the method of  claim 1 . 
     
     
         28 . A FACS-sorted cell population containing (a) at least 2, at least 5 or at least 10 and/or (b) up to 15, up to 25, or up to 35 fNRBCs enriched from maternal blood. 
     
     
         29 - 30 . (canceled) 
     
     
         31 . A method of detecting a fetal abnormality, comprising analyzing at least one fNRBC from the cell population of  claim 27  for a fetal abnormality. 
     
     
         32 . (canceled) 
     
     
         33 . The method of  claim 31 , which comprises analyzing a single fNRBC for the fetal abnormality. 
     
     
         34 . The method of  claim 31 , which comprises analyzing a group of fNRBCs for the fetal abnormality. 
     
     
         35 - 38 . (canceled) 
     
     
         39 . The method of  claim 31 , which further comprises validating the fNRBC or fNRBCs as fetal cells. 
     
     
         40 - 42 . (canceled)

Join the waitlist — get patent alerts

Track US2019376033A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.